Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed, newly diagnosed, unilateral primary non-small cell lung cancer (NSCLC) Must have involvement of the superior sulcus, chest wall, or mediastinum Must have at least 1 of the following: Locally advanced Pancoast tumors with no documented mediastinal or supraclavicular nodal involvement (T3-T4, N0-1) Resectable chest wall disease (T3, N0-1) Marginally resectable T4, N0-1, or NX central NSCLC N2 patients who are potentially resectable after induction chemoradiotherapy No evidence of extrathoracic spread to liver, adrenals, brain, or bone No evidence of supraclavicular nodes, malignant pleural or pericardial effusions, or distant metastases PATIENT CHARACTERISTICS: Age 18 and over Performance status Karnofsky 70-100% Life expectancy Not specified Hematopoietic Absolute neutrophil count at least 2,000/mm^3 Platelet count at least 100,000/mm^3 Hepatic Bilirubin no greater than 1.5 mg/dL SGOT no greater than 3 times upper limit of normal Renal Creatinine no greater than 2.0 mg/dL Cardiovascular No superior vena cava syndrome No myocardial infarction within the past 6 months No active uncontrolled congestive heart failure No active uncontrolled arrhythmia within the past 6 months Pulmonary FEV1 at least 800 mL Other No other active invasive malignancy requiring therapy within the past 2 years No ongoing need for adjuvant therapy Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for at least 3 months after study entry PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy No prior pelvic or thoracic radiotherapy Surgery See Disease Characteristics Other Concurrent beta blockers, digitalis derivatives, or channel-blocking agents allowed provided cardiac conditions are stable